Advancing Newborn Screening in Washington State: A Novel Multiplexed LC-MS/MS Proteomic Assay for Wilson Disease and Inborn Errors of Immunity
International Journal of Neonatal Screening · 10.01.2025 · 11 (1) · 6
DOI: 10.3390/ijns11010006 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Neonatal Screening, online erschienen am 10.01.2025. Verfasst von Claire Klippel und 14 weiteren Autor:innen. Beteiligte Einrichtung: Key Proteo, Inc., Seattle, WA 98122, USA. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NICHD NIH HHS, NIH HHS, NIH.
Abstract (Originalsprache)
For many genetic disorders, there are no specific metabolic biomarkers nor analytical methods suitable for newborn population screening, even where highly effective preemptive treatments are available. The direct measurement of signature peptides as a surrogate marker for the protein in dried blood spots (DBSs) has been shown to successfully identify patients with Wilson Disease (WD) and three life-threatening inborn errors of immunity, X-linked agammaglobulinemia (XLA), Wiskott–Aldrich syndrome (WAS), and adenosine deaminase deficiency (ADAD). A novel proteomic-based multiplex assay to detect these four conditions from DBS using high-throughput LC-MS/MS was developed and validated. The clinical validation results showed that the assay can accurately identify patients of targeted disorders from controls. Additionally, 30,024 newborn DBS samples from the Washington State Department of Health Newborn Screening Laboratory have been screened from 2022 to 2024. One true presumptive positive case of WD was found along with three false positive cases. Five false positives for WAS were detected, but all of them were premature and/or low-birth-weight babies and four of them had insufficient DNA for confirmation. The pilot study demonstrates the feasibility and effectiveness of utilizing this multiplexed proteomic assay for newborn screening.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Key Proteo, Inc., Seattle, WA 98122, USA.
- Alberta Precision Laboratories, Calgary, AB T2L 2K8, Canada.
- Washington State Department of Health Newborn Screening Laboratories, Seattle, WA 98155, USA.
- Seattle Children's Research Institute, Seattle, WA 98105, USA.
ORCID-Profile: Jiwoon Park, Dennis Orton
Förderung
- NICHD NIH HHS
- NIH HHS
- NIH
Zitieren
APA
Klippel, C., Park, J., Sandin, S., Winstone, T. M. L., Chen, X., Orton, D., Singh, A., Hill, J. D., Shahbal, T. K., Hamacher, E., Officer, B., Thompson, J., Duong, P., Grotzer, T., & Hahn, S. H. (2025). Advancing Newborn Screening in Washington State: A Novel Multiplexed LC-MS/MS Proteomic Assay for Wilson Disease and Inborn Errors of Immunity. International Journal of Neonatal Screening, 11(1), 6. https://doi.org/10.3390/ijns11010006
Vancouver
Klippel C, Park J, Sandin S, Winstone TML, Chen X, Orton D, et al. Advancing Newborn Screening in Washington State: A Novel Multiplexed LC-MS/MS Proteomic Assay for Wilson Disease and Inborn Errors of Immunity. International Journal of Neonatal Screening. 2025;11(1):6. doi:10.3390/ijns11010006
BibTeX
@article{Klippel2025,
author = {Klippel, Claire and Park, Jiwoon and Sandin, Sean and Winstone, Tara M L and Chen, Xue and Orton, Dennis and Singh, Aranjeet and Hill, Jonathan D and Shahbal, Tareq K and Hamacher, Emily and Officer, Brandon and Thompson, John and Duong, Phi and Grotzer, Tim and Hahn, Si Houn},
title = {Advancing Newborn Screening in Washington State: A Novel Multiplexed LC-MS/MS Proteomic Assay for Wilson Disease and Inborn Errors of Immunity},
journal = {International Journal of Neonatal Screening},
year = {2025},
volume = {11},
number = {1},
pages = {6},
doi = {10.3390/ijns11010006}
}
EUVIMED